Overview

Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome

Status:
Active, not recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This study is designed to compare the safety and effectiveness of two blood thinners, apixaban and warfarin, for the prevention of blood clots in patients who have a higher risk of blood clots than the general population, a condition called "antiphospholipid syndrome".

Phase:

Phase 4

Details

Lead Sponsor:

Intermountain Health Care, Inc.
Scott C. Woller, MD

Collaborators:

Bristol-Myers Squibb
University of Utah

Treatments:

Apixaban
Warfarin